CN105902515B - 纳米药物存储器、其制备方法及其应用 - Google Patents
纳米药物存储器、其制备方法及其应用 Download PDFInfo
- Publication number
- CN105902515B CN105902515B CN201610334823.7A CN201610334823A CN105902515B CN 105902515 B CN105902515 B CN 105902515B CN 201610334823 A CN201610334823 A CN 201610334823A CN 105902515 B CN105902515 B CN 105902515B
- Authority
- CN
- China
- Prior art keywords
- nano medication
- drug
- solution
- memory
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 91
- 229940079593 drug Drugs 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 229920001577 copolymer Polymers 0.000 claims abstract description 13
- ZIQCCIAIROIHHR-UHFFFAOYSA-N benzene;boric acid Chemical compound OB(O)O.C1=CC=CC=C1 ZIQCCIAIROIHHR-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000001338 self-assembly Methods 0.000 claims abstract description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 230000000857 drug effect Effects 0.000 claims abstract description 4
- 229960003511 macrogol Drugs 0.000 claims abstract description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 27
- 150000004676 glycans Chemical class 0.000 claims description 10
- 229920001282 polysaccharide Polymers 0.000 claims description 10
- 239000005017 polysaccharide Substances 0.000 claims description 10
- 239000000017 hydrogel Substances 0.000 claims description 9
- 238000001704 evaporation Methods 0.000 claims description 6
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 claims description 4
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 claims description 4
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 claims description 4
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 claims description 4
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 claims description 4
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 claims description 4
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 claims description 4
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 claims description 4
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 claims description 4
- 229940058690 lanosterol Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000002834 transmittance Methods 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- 230000010355 oscillation Effects 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000010409 thin film Substances 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 238000001727 in vivo Methods 0.000 abstract description 9
- 230000007281 self degradation Effects 0.000 abstract description 5
- 239000002537 cosmetic Substances 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 210000001124 body fluid Anatomy 0.000 abstract description 3
- 239000010839 body fluid Substances 0.000 abstract description 3
- 230000015556 catabolic process Effects 0.000 abstract description 3
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 239000002207 metabolite Substances 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 22
- 238000013270 controlled release Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- LXDRHVXMGDKBEK-UHFFFAOYSA-N [B].C1=CC=CC=C1 Chemical compound [B].C1=CC=CC=C1 LXDRHVXMGDKBEK-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
细胞种类 | 血管细胞 | 上皮细胞 | 肌肉细胞 | 肝细胞 |
细胞存活率(一天) | >97% | >98% | >94% | >96% |
细胞存活率(一个月) | >99% | >98% | >97% | >99% |
细胞因子 | IL-12 | TNF-α | IL6 | IL8 | IFNγ | LDH |
正常值 | 2.9-53.9 | 0-32.5 | 0-12.7 | 0-50.4 | 0-1.5 | 140-280 |
植入后一天 | 22.1±3.4 | 10.9±11.2 | 4.6±1.6 | 17.1±8.1 | 0.56±0.2 | 202±17 |
植入后一个月 | 28.4±10.9 | 19.7±4.2 | 8.1±1.7 | 29±11.7 | 0.66±0.3 | 209±52 |
植入后四个月 | 27.3±8.3 | 19.2±6.5 | 7.0±1.5 | 19±11.2 | 0.63±0.4 | 206±19 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610334823.7A CN105902515B (zh) | 2016-05-19 | 2016-05-19 | 纳米药物存储器、其制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610334823.7A CN105902515B (zh) | 2016-05-19 | 2016-05-19 | 纳米药物存储器、其制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105902515A CN105902515A (zh) | 2016-08-31 |
CN105902515B true CN105902515B (zh) | 2019-04-05 |
Family
ID=56749493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610334823.7A Active CN105902515B (zh) | 2016-05-19 | 2016-05-19 | 纳米药物存储器、其制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105902515B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10738076B2 (en) | 2017-01-25 | 2020-08-11 | Zhongshan Ophthalmic Center, Sun Yat-Sen University | Lanosterol prodrug compound and preparation method therefor and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104856943A (zh) * | 2015-06-08 | 2015-08-26 | 厦门普瑞安生物科技有限公司 | Plga-peg-plga三嵌段共聚物在载药和缓释药物中的用途及其制备方法 |
CN104892912A (zh) * | 2015-06-08 | 2015-09-09 | 厦门普瑞安生物科技有限公司 | 一种plga-peg-plga三嵌段共聚物及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1343530E (pt) * | 2000-11-09 | 2007-09-25 | Astrazeneca Ab | Composição farmacêutica oral contendo um copolímero de blocos |
-
2016
- 2016-05-19 CN CN201610334823.7A patent/CN105902515B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104856943A (zh) * | 2015-06-08 | 2015-08-26 | 厦门普瑞安生物科技有限公司 | Plga-peg-plga三嵌段共聚物在载药和缓释药物中的用途及其制备方法 |
CN104892912A (zh) * | 2015-06-08 | 2015-09-09 | 厦门普瑞安生物科技有限公司 | 一种plga-peg-plga三嵌段共聚物及其制备方法 |
Non-Patent Citations (4)
Title |
---|
刘迪等."PLGA及PLGA-PEG-PLGA水凝胶的制备".《厦门大学学报(自然科学版)》.2016,第55卷(第2期),第162-167页. |
宋伟."羊毛甾醇可以减轻白内障".《生理科学进展》.2015,第46卷(第5期),第346页. |
席陈彬等."聚乙二醇-聚乳酸-聚甲基丙烯酸羟乙酯两亲性三嵌段聚合物的合成及其自组装研究".《有机化学》.2012,第32卷第2166-2170页. |
杨挺等."基于含苯硼酸三嵌段共聚物的糖响应性水凝胶".《高分子学报》.2014,(第11期),第1553-1560页. |
Also Published As
Publication number | Publication date |
---|---|
CN105902515A (zh) | 2016-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Severino et al. | Alginate nanoparticles for drug delivery and targeting | |
Suhail et al. | Nanogels as drug-delivery systems: A comprehensive overview | |
Herdiana et al. | Drug release study of the chitosan-based nanoparticles | |
Zavareh et al. | Chitosan/carbon quantum dot/aptamer complex as a potential anticancer drug delivery system towards the release of 5-fluorouracil | |
Luo et al. | Zein‐based micro‐and nano‐particles for drug and nutrient delivery: A review | |
Tomaro-Duchesneau et al. | Microencapsulation for the therapeutic delivery of drugs, live mammalian and bacterial cells, and other biopharmaceutics: current status and future directions | |
Dhanka et al. | Methotrexate loaded gellan gum microparticles for drug delivery | |
Dhanka et al. | Injectable methotrexate loaded polycaprolactone microspheres: physicochemical characterization, biocompatibility, and hemocompatibility evaluation | |
Zarekar et al. | Nanogel as a novel platform for smart drug delivery system | |
Kendre et al. | Current trends and concepts in the design and development of nanogel carrier systems | |
Far et al. | Developing biodegradable nanoparticles loaded with mometasone furoate for potential nasal drug delivery | |
Ryu et al. | Dry tablet formulation of PLGA nanoparticles with a preocular applicator for topical drug delivery to the eye | |
CA2615939A1 (en) | Microdevices comprising nanocapsules for controlled delivery of drugs and method of manufacturing same | |
CN113226293B (zh) | 利用壳聚糖涂覆的纳米胶囊及其用途 | |
Jiang et al. | PLGA nanoparticle platform for trans-ocular barrier to enhance drug delivery: a comparative study based on the application of oligosaccharides in the outer membrane of carriers | |
Yadav et al. | Screening of ionically crosslinked chitosan-tripolyphosphate microspheres using Plackett–Burman factorial design for the treatment of intrapocket infections | |
Manimaran et al. | Nanogels as novel drug nanocarriers for CNS drug delivery | |
Mullaicharam | Nanoparticles in drug delivery system | |
Bhujbal et al. | Metformin-loaded hyaluronic acid nanostructure for oral delivery | |
Villalba-Rodriguez et al. | Bio-inspired biomaterials and their drug delivery perspectives-A review | |
Tariq et al. | Nanogel-Based transdermal drug delivery system: A therapeutic strategy with under discussed potential | |
CN105902515B (zh) | 纳米药物存储器、其制备方法及其应用 | |
Patel et al. | A review-Recent research on microsponge a novel new drug delivery system | |
Chang et al. | The new ophthalmic formulation for infection control by combining collagen/gelatin/alginate biomaterial with liposomal chloramphenicol | |
Enwereuzo et al. | Self-assembled membrane-polymer nanoparticles of top-notch tissue tolerance for the treatment of gastroesophageal reflux disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20181008 Address after: 315040 Zhejiang Ningbo High-tech Zone 6 Jingyuan road 13, 1301-1305 room. Applicant after: NINGBO HYGEIA MEDICAL TECHNOLOGY CO.,LTD. Address before: 200011 6 Lane 201 Tibet South Road, Huangpu District, Shanghai 201 Applicant before: Liu Jun |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231012 Address after: Room 106, Building 4, No. 288 Development Avenue, Gaoqiao Street (Development Zone), Tongxiang City, Jiaxing City, Zhejiang Province, 314515 Patentee after: Jiaxing Qingzhun Pharmaceutical Technology Co.,Ltd. Address before: 315040 Zhejiang Ningbo High-tech Zone 6 Jingyuan road 13, 1301-1305 room. Patentee before: NINGBO HYGEIA MEDICAL TECHNOLOGY CO.,LTD. |